We utilized the commercialized IL‐6R mAb Tocilizumab, of which SIRS is a candidate disease, as treatment for the positive control group and analyzed the survival time of LPS‐induced SIRS mice with the h‐mIL‐6R or Tocilizumab treatment.8 Here, IL6R is linked to systemic inflammatory response syndrome.